Search

Your search keyword '"Houssel-Debry, P"' showing total 15 results
Start Over Author "Houssel-Debry, P" Journal journal of hepatology
15 results on '"Houssel-Debry, P"'

1. Baseline serum ferritin is an independent predictive factor of mortality in patients with chronic hepatitis C after long term follow-up

Author

Jezequel, C., primary, Ali, Z.B., additional, Pronier, C., additional, Rabot, A., additional, Renard, I., additional, Legros, L., additional, Uguen, T., additional, Bardou-Jacquet, E., additional, Lan, C.L., additional, Moirand, R., additional, Houssel-Debry, P., additional, Michelet, C., additional, Thibault, V., additional, and Guyader, D., additional

Published
2017
Full Text
View/download PDF

2. Treatment and prognosis of acute severe autoimmune hepatitis

Author

De Martin, E., primary, Coilly, A., additional, Houssel-Debry, P., additional, Ollivier-Hourmand, I., additional, Heurgue-Berlot, A., additional, Artru, F., additional, Barge, S., additional, Chazouilleres, O., additional, Silvain, C., additional, Duvoux, C., additional, Pageaux, G.-P., additional, Besch, C., additional, Bourlière, M., additional, Fontaine, H., additional, de Ledinghen, V., additional, Dumortier, J., additional, Conti, F., additional, Radenne, S., additional, Debette-Gratien, M., additional, Goria, O., additional, Boursier, J., additional, Peron, J.-M., additional, Durand, F., additional, Borrentain, P., additional, Potier, P., additional, Minello, A., additional, Abergel, A., additional, Perarnau, J.-M., additional, Nousbaum, J.-B., additional, Rudler, M., additional, Alric, L., additional, Anty, R., additional, Sturm, N., additional, Sebagh, M., additional, Agostini, H., additional, Samuel, D., additional, and Duclos-Vallée, J.-C., additional

Published
2017
Full Text
View/download PDF

3. Should we keep using Ribavirin to Treat Hepatitis C Recurrence after Liver Transplantation? Results from the CO23 ANRS Cupilt Study

Author

Houssel-Debry, P., primary, Duvoux, C., additional, Coilly, A., additional, Fougerou-Leurent, C., additional, Jezequel, C., additional, De Ledinghen, V., additional, Radenne, S., additional, Kamar, N., additional, Leroy, V., additional, Di Martino, V., additional, D’Alteroche, L., additional, Canva, V., additional, Conti, F., additional, Dumortier, J., additional, Montialoux, H., additional, Lebray, P., additional, Botta-Fridlund, D., additional, Anty, R., additional, Moreno, C., additional, Silvain, C., additional, Besch, C., additional, Perre, P., additional, Durand, F., additional, Abergel, A., additional, Habersetzer, F., additional, Debette-Gratien, M., additional, Rohel, A., additional, Diallo, A., additional, Rossignol, E., additional, Veislinger, A., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional

Published
2016
Full Text
View/download PDF

4. Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt

Author

Anty, R., primary, Coilly, A., additional, Fougerou, C., additional, De Ledinghen, V., additional, Houssel-Debry, P., additional, Duvoux, C., additional, Di Martino, V., additional, Radenne, S., additional, Kamar, N., additional, D’Alteroche, L., additional, Canva, V., additional, Lebray, P., additional, Moreno, C., additional, Dumortier, J., additional, Silvain, C., additional, Besch, C., additional, Botta-Fridlund, D., additional, Leroy, V., additional, Durand, F., additional, Tran, A., additional, Montialoux, H., additional, Habersetzer, F., additional, Favre, G., additional, Rossignol, E., additional, Rohel, A., additional, Renault, A., additional, Dharancy, S., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional

Published
2016
Full Text
View/download PDF

5. Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study

Author

Dharancy, S., primary, Coilly, A., additional, Fougerou-Leurent, C., additional, Duvoux, C., additional, Kamar, N., additional, Leroy, V., additional, Tran, A., additional, Houssel-Debry, P., additional, Canva, V., additional, Moreno, C., additional, Conti, F., additional, Dumortier, J., additional, Di Martino, V., additional, Radenne, S., additional, De Ledinghen, V., additional, D’Alteroche, L., additional, Silvain, C., additional, Besch, C., additional, Perré, P., additional, Botta-Fridlund, D., additional, Francoz, C., additional, Habersetzer, F., additional, Montialoux, H., additional, Abergel, A., additional, Debette-Gratien, M., additional, Rohel, A., additional, Vallée, J.C.D., additional, and Pageaux, G.-P., additional

Published
2016
Full Text
View/download PDF

6. P0804 : Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study

Author

Antonini, T.M., primary, Coilly, A., additional, Radenne, S., additional, Veislinger, A., additional, Botta-Fridlund, D., additional, Durand, F., additional, Houssel-Debry, P., additional, Kamar, N., additional, Canva, V., additional, Perre, P., additional, Bertucci, I., additional, Dumortier, J., additional, Leroy, V., additional, Samuel, D., additional, Pageaux, G.-P., additional, and Duclos-Vallee, J.-C., additional

Published
2015
Full Text
View/download PDF

8. G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort

Author

Coilly, A., primary, Fougerou, C., additional, De Ledinghen, V., additional, Houssel-Debry, P., additional, Duvoux, C., additional, Di Martino, V., additional, Radenne, S., additional, Kamar, N., additional, D’Alteroche, L., additional, Leroy, V., additional, Canva, V., additional, Lebray, P., additional, Moreno, C., additional, Dumortier, J., additional, Silvain, C., additional, Besch, C., additional, Perre, P., additional, Botta-Fridlund, D., additional, Anty, R., additional, Rohel, A., additional, Renault, A., additional, Danjou, H., additional, Duclos-Vallee, J.-C., additional, and Pageaux, G.-P., additional

Published
2015
Full Text
View/download PDF

9. O109 : Treatment of severe HCV-recurrence after liver transplantation using sofosbuvir-based regimens: The ANRS CO23 CUPILT study

Author

Dumortier, J., primary, Botta-Fridlund, D., additional, Coilly, A., additional, Leroy, V., additional, Fougerou-Leurent, C., additional, Danjou, H., additional, Radenne, S., additional, Durand, F., additional, Kamar, N., additional, di Martino, V., additional, de Ledinghen, V., additional, Houssel-Debry, P., additional, d’Alteroche, L, additional, Duvoux, C., additional, Conti, F., additional, Canva, V., additional, Diallo, A., additional, Rohel, A., additional, Duclos-Vallée, J.-C., additional, and Pageaux, G.-P., additional

Published
2015
Full Text
View/download PDF

10. P743 IMPACT OF BASELINE SERUM FERRITIN ON SURVIVAL OF PATIENTS WITH CHRONIC HEPATITIS C AFTER A 15 YEARS FOLLOW-UP

Author

Jézéquel, C., primary, Bardou-Jacquet, E., additional, Désille, Y., additional, Renard, I., additional, Latournerie, M., additional, Houssel-Debry, P., additional, Le Gruyer, A., additional, Guillygomarc'h, A., additional, Le Lan, C., additional, Brissot, P., additional, Moirand, R., additional, Deugnier, Y., additional, Lainé, F., additional, Loréal, O., additional, Turlin, B., additional, and Guyader, D., additional

Published
2014
Full Text
View/download PDF

11. FRI-481 - Renal Dysfunction in Liver Transplant Patients Treated with Sofosbuvir Based-Regimen for HCV Recurrence: Results from a Large French Prospective Multicentric ANRS CO23 Cupilt

Author

Anty, R., Coilly, A., Fougerou, C., De Ledinghen, V., Houssel-Debry, P., Duvoux, C., Di Martino, V., Radenne, S., Kamar, N., D’Alteroche, L., Canva, V., Lebray, P., Moreno, C., Dumortier, J., Silvain, C., Besch, C., Botta-Fridlund, D., Leroy, V., Durand, F., Tran, A., Montialoux, H., Habersetzer, F., Favre, G., Rossignol, E., Rohel, A., Renault, A., Dharancy, S., Danjou, H., Duclos-Vallee, J.-C., and Pageaux, G.-P.

Published
2016
Full Text
View/download PDF

12. FRI-483 - Sofosbuvir-Based-Regimen for HCV Recurrence after Combined Liver-Kidney Transplantation : Results from the ANRS CO23 Cupilt Study

Author

Dharancy, S., Coilly, A., Fougerou-Leurent, C., Duvoux, C., Kamar, N., Leroy, V., Tran, A., Houssel-Debry, P., Canva, V., Moreno, C., Conti, F., Dumortier, J., Di Martino, V., Radenne, S., De Ledinghen, V., D’Alteroche, L., Silvain, C., Besch, C., Perré, P., Botta-Fridlund, D., Francoz, C., Habersetzer, F., Montialoux, H., Abergel, A., Debette-Gratien, M., Rohel, A., Vallée, J.C.D., and Pageaux, G.-P.

Published
2016
Full Text
View/download PDF

13. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score.

Author

De Martin E, Coilly A, Chazouillères O, Roux O, Peron JM, Houssel-Debry P, Artru F, Silvain C, Ollivier-Hourmand I, Duvoux C, Heurgue A, Barge S, Ganne-Carrié N, Pageaux GP, Besch C, Bourlière M, Fontaine H, de Ledinghen V, Dumortier J, Conti F, Radenne S, Debette-Gratien M, Goria O, Durand F, Potier P, Di Martino V, Reboux N, Ichai P, Sebagh M, Mathurin P, Agostini H, Samuel D, and Duclos-Vallée JC

Subjects
Acute Disease, Adult, Aged, Female, Follow-Up Studies, Hepatitis, Autoimmune blood, Hepatitis, Autoimmune surgery, Humans, Liver Failure, Acute blood, Liver Failure, Acute surgery, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Rate, Treatment Failure, Adrenal Cortex Hormones therapeutic use, Bilirubin blood, Hepatitis, Autoimmune drug therapy, Hepatitis, Autoimmune mortality, International Normalized Ratio methods, Liver Failure, Acute drug therapy, Liver Failure, Acute mortality, Liver Transplantation methods, Severity of Illness Index
Abstract

Background & Aims: In acute severe autoimmune hepatitis (AS-AIH), the optimal timing for liver transplantation (LT) remains controversial. The objectives of this study were to determine early predictive factors for a non-response to corticosteroids and to propose a score to identify patients in whom LT is urgently indicated., Methods: This was a retrospective, multicenter study (2009-2016). A diagnosis of AS-AIH was based on: i) Definite or probable AIH based on the simplified IAIHG score; ii) international normalized ratio (INR) ≥1.5 and/or bilirubin >200 μmol/L; iii) No previous history of AIH; iv) Histologically proven AIH. A treatment response was defined as LT-free survival at 90 days. The evolution of variables from corticosteroid initiation (day-D0) to D3 was estimated from: Δ%3 = (D3-D0)/D0., Results: A total of 128 patients were included, with a median age of 52 (39-62) years; 72% were female. Overall survival reached 88%. One hundred and fifteen (90%) patients received corticosteroids, with a LT-free survival rate of 66% at 90 days. Under multivariate analysis, D0-INR (odds ratio [OR] 6.85; 95% CI 2.23-21.06; p <0.001), Δ%3-INR ≥0.1% (OR 6.97; 95% CI 1.59-30.46; p <0.01) and Δ%3-bilirubin ≥-8% (OR 5.14; 95% CI 1.09-24.28; p <0.04) were predictive of a non-response. The SURFASA score: -6.80+1.92∗(D0-INR)+1.94∗(Δ%3-INR)+1.64∗(Δ%3-bilirubin), created by combining these variables, was highly predictive of LT or death (AUC = 0.93) (88% specificity; 84% sensitivity) with a cut-off point of <-0.9. Below this cut-off, the chance of responding was 75%. With a score higher than 1.75, the risk of dying or being transplanted was between 85% and 100%., Conclusion: In patients with AS-AIH, INR at the introduction of corticosteroids and the evolution of INR and bilirubin are predictive of LT or death. Within 3 days of initiating corticosteroids, the SURFASA score can identify non-responders who require a referral for LT. This score needs to be validated in a prospective cohort., Lay Summary: The management of patients with acute severe autoimmune hepatitis is highly challenging, particularly regarding their early referral for liver transplantation. We found that international normalized ratio at the initiation of corticosteroid therapy and the evolution of international normalized ratio and bilirubin values after 3 days of therapy were highly predictive of liver transplantation or death. We are thus proposing a score that combines these variables and identifies patients in whom liver transplantation is urgently required., Competing Interests: Conflict of interest EDM: nothing to disclose, AC: nothing to disclose, OC: nothing to disclose, OR: nothing to disclose, JMP: nothing to disclose, PHD: nothing to disclose, FA: nothing to disclose, CS: nothing to disclose, IOH: nothing to disclose, CD: nothing to disclose, AHB: nothing to disclose, SB: nothing to disclose, NG: nothing to disclose, GPP: nothing to disclose, CB: nothing to disclose, MB: nothing to disclose, HF: nothing to disclose, VdL: nothing to disclose, JD: nothing to disclose, FC: nothing to disclose, SR: nothing to disclose, MDG: nothing to disclose, OG: nothing to disclose, FD: nothing to disclose, PP: nothing to disclose, VDM: nothing to disclose, NR: nothing to disclose, PI: nothing to disclose, MS: nothing to disclose, PM: nothing to disclose, HA: nothing to disclose, DS: nothing to disclose, JCDV: nothing to disclose. Please refer to the accompanying ICMJE disclosure forms for further details., (Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)

Published
2021
Full Text
View/download PDF

14. Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.

Author

Mouna L, Rossignol E, Tateo M, Coilly A, Duclos-Vallée JC, Duvoux C, Durand F, Tran A, Radenne S, Canva-Delcambre V, Houssel-Debry P, Dumortier J, Conti F, de Ledinghen V, Leroy V, Kamar N, Di Martino V, Moreno C, Botta Fridlund D, d'Alteroche L, Lebray P, Perre P, Besch C, Silvain C, Habersetzer F, Debette-Gratien M, Abergel A, Diallo A, Samuel D, Roque-Afonso AM, and Pageaux GP

Subjects
DNA, Viral blood, Hepatitis B virus drug effects, Hepatitis C virology, Humans, Prospective Studies, Recurrence, Antiviral Agents therapeutic use, Hepatitis B prevention & control, Hepatitis B virus physiology, Hepatitis C drug therapy, Liver Transplantation adverse effects, Virus Activation
Published
2019
Full Text
View/download PDF

15. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.

Author

Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V, Radenne S, Kamar N, D'Alteroche L, Leroy V, Canva V, Lebray P, Moreno C, Dumortier J, Silvain C, Besch C, Perre P, Botta-Fridlund D, Anty R, Francoz C, Abergel A, Debette-Gratien M, Conti F, Habersetzer F, Rohel A, Rossignol E, Danjou H, Roque-Afonso AM, Samuel D, Duclos-Vallée JC, and Pageaux GP

Subjects
Antiviral Agents, Compassionate Use Trials, Drug Therapy, Combination, France, Hepacivirus, Humans, Prospective Studies, Ribavirin, Sofosbuvir, Treatment Outcome, Hepatitis C
Abstract

Background & Aims: HCV recurrence remains a major issue in the liver transplant field, as it has a negative impact on both graft and patient survival. The purpose of this study was to investigate the efficacy and safety of treating HCV recurrence with sofosbuvir (SOF) and daclatasvir (DCV) combination therapy., Methods: From October 2013 to March 2015, 559 liver recipients were enrolled in the prospective multicentre France REcherche Nord&Sud Sida-hiv Hépatites (ANRS) Compassionate use of Protease Inhibitors in viral C Liver Transplantation cohort. We selected 137 patients with an HCV recurrence receiving SOF and DCV, whatever the genotype or fibrosis stage. The use of ribavirin and the duration of therapy were at the investigator's discretion. The primary efficacy end point was a sustained virological response (SVR) 12weeks after the end of treatment., Results: The SVR rate 12weeks after completing treatment was 96% under the intention-to treat analysis and 99% when excluding non-virological failures. Only two patients experienced a virological failure. The serious adverse event (SAE) rate reached 17.5%. Four patients (3%) stopped their treatment prematurely because of SAEs. Anaemia was the most common AE, with significantly more cases in the ribavirin group (56% vs. 18%; p<0.0001). A slight but significant reduction in creatinine clearance was reported. No clinically relevant drug-drug interactions were noted, but 52% of patients required a change to the dosage of immunosuppressive drugs., Conclusions: Treatment with SOF plus DCV was associated with a high SVR12 and low rates of serious adverse events among liver recipients with HCV recurrence., Lay Summary: The recurrence of hepatitis C used to be the first cause of graft failure in infected liver transplanted recipients. Our study demonstrates the great efficacy of one combination of new all-oral direct-acting antiviral, sofosbuvir and daclatasvir, to treat the recurrence of hepatitis C on the graft. Ninety-six per cent of recipients were cured. The safety profile of this combination seemed to be good, especially no relevant drug-drug interaction with immunosuppressive drugs., (Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results